PK, PD and interactions: the new scenario with JAK inhibitors and S1P Receptor Modulators, two classes of small molecule drugs, in IBD.

Date publication

juin 2020

Journal

Expert review of gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-Biroulet L, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32571107

Résumé

Inflammatory bowel disease (IBD) are immune-mediated chronic inflammatory disorders of the gastrointestinal tract whose pathogenesis is not yet fully understood. Despite the advent of biological agents, there are still unmet needs for IBD patients, due to suboptimal rate of sustained remission achieved. Small molecule drugs (SMDs), the next generation of selective drugs in IBD, show promising results in ongoing trials.

Mots clés

Cytochrome P450s, Drug-drug interactions, Janus Kinase inhibitors, Pharmacodynamics, Pharmacokinetics, Small Molecule Drugs, Sphingosine-1-Phosphate Receptor Modulators, inflammatory bowel disease

Référence

Expert Rev Gastroenterol Hepatol. 2020 Jun 22;: